The collaboration creates one-stop source for high-end diagnostic and therapeutic vision care technologies
Lumenis Ltd., the world’s largest medical laser company for ophthalmic, aesthetic, and surgical applications, and Visionix, a worldwide leader in wavefront technology for visual acuity and lens mapping, announced today a strategic agreement for Lumenis to distribute the Visionix ophthalmic and optometric diagnostics product line in China. The Lumenis-Visionix partnership will create a one-stop source for a comprehensive line of vision care diagnostic devices and therapeutic lasers, allowing ophthalmologists and optometrists to offer their patients cost-effective and clinically-proven vision solutions.
The Chinese vision care market is growing by double-digits as the country’s middle class increases in size and access to health care improves. This newly announced partnership with Visionix will allow Lumenis to build on its robust presence in the Asia Pacific region and further expands its product offering.
“We are delighted to partner with Visionix; and to offer their innovative, intuitive and cost-effective solutions to our ophthalmology and optometry customers in China,” said Mr. Qiying Zhai, President of Lumenis Asia-Pacific. “The Visionix diagnostic technology is a perfect complement to expand Lumenis’ portfolio and capitalizes on our strong presence and operations in the vision care market in the fast-growing Asia-Pacific Region.”
Lumenis offers the industry’s most extensive and clinically-proven line of ophthalmic lasers to preserve and improve vision. The Company’s lasers are now a standard tool to treat many sight-threatening diseases, including diabetic retinopathy, glaucoma, and secondary cataracts.
Visionix is the pioneer of the world’s first true wavefront based refraction line. The Visionix ophthalmic and optometric diagnostic products that Lumenis will be distributing in China include phoropters, Wavefront aberometers, visual field analyzer slit lamps and lens edging system.
“In the ophthalmology world, Lumenis has built an unparalleled track record for delivering technological breakthroughs and our products are used as the industry gold-standard for glaucoma and retina treatments,” said Mr. Kfir Azoulay, Vice President and General Manager of Lumenis’ global ophthalmology business. “Visionix also has a reputation as a technology leader, so this distribution agreement lays the foundation for broader future collaboration. We are thrilled to now offer our customers in the high-growth Chinese market a continuum of solutions, ranging from diagnostic to therapeutic vision care products.”
“We are very excited to embark on this strategic alliance with Lumenis as our two companies’ product lines complement each other perfectly,” said Dr. Marc Abitbol, President and CEO of Visionix. “Lumenis is renowned in the ophthalmic industry for its performance, customer support and strong brand name. This business cooperation will allow the Visionix team to continue developing outstanding ophthalmic and optometry diagnostic products that exceed customer expectations, while meaningfully increasing our global market reach into emerging markets.”
